Qiagen, a biotechnology company, appears to be on the radar of several major buyout firms as a potential acquisition target, Bloomberg News reported on Thursday.
According to Bloomberg, citing individuals with knowledge of the situation, the firms showing early interest in a possible takeover include EQT AB, Advent, and KKR.
Reuters, which initially reported on the Bloomberg story, noted that it was unable to immediately confirm the information independently.
